All Open Clinical Trials
Below is a list of all open NCI Center for Cancer Research (CCR) clinical trials, including studies that are currently recruiting patients (i.e. Open - Recruiting) as well as trials that will be recruiting soon (i.e., Open - Not yet Recruiting). Most recently opened trials are listed first.
All CCR clinical trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States.
-
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0046Investigator James N. Kochenderfer, M.D. -
Long term follow-up of mesothelioma patients and their family members with germline mutations in BAP1 and other genes
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0049Investigator Raffit Hassan, M.D. -
A Phase I study of Moxetumomab pasudotox (Lumoxiti™) and Rituximab (Rituxan®) for Relapsed Hairy Cell Leukemia
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0042Investigator Robert J. Kreitman, M.D. -
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0040Investigator William L. Dahut, M.D. -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0039Investigator Jonathan M. Hernandez, M.D. -
An open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2287411 Injection, in patients with solid tumors known to express
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0038Investigator Raffit Hassan, M.D. -
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0033Investigator Tim F. Greten, M.D. -
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma #xD;
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0030Investigator Mark Roschewski, M.D. -
Tissue Acquisition and Genomics Analysis of Breast and Other Gynecologic Malignancies
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0025Investigator Christina M. Annunziata, M.D., Ph.D. -
A Phase II Study of Olaparib in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0023Investigator Andrea B. Apolo, M.D. -
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0024Investigator Milos Miljković, M.D., M.Sc. -
A Natural History Study of Children and Adults with Fibrolamellar Hepatocellular Carcinoma
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0021Investigator Tim F. Greten, M.D. -
A Randomized Phase 2 Trial of Durvalumab (MEDI4736) with or without SBRT in Clinical Stage I, II, and IIIA Non-Small Cell Lung Cancer (NSCLC)
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0018Investigator David S. Schrump, M.D., M.B.A. -
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Open - RecruitingNCI Protocol ID NCI-19-C-0017Investigator James C. Yang, M.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Natural History and Biospecimen Accrual Study for Children and Adults with Rare Solid Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0016Investigator Jaydira Del Rivero, M.D. -
Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0011Investigator Mark R. Gilbert, M.D.Share this trial: Referral ContactsContact Name Phone Number Ann McCoy 240-760-6021 Christine Bryla 240-760-6007 -
Phase II trial evaluating Nivolumab in patients with IDH-mutant gliomas with and without hypermutator phenotype
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0006Investigator Jing Wu, M.D., Ph.D. -
A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis
Open - RecruitingNCI Protocol ID NCI-19-C-0002Investigator Christian S. Hinrichs, M.D. -
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-resistant Solid Tumors
Open - RecruitingNCI Protocol ID NCI-18-C-0147Investigator Christina M. Annunziata, M.D., Ph.D. -
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior
Open - RecruitingNCI Protocol ID NCI-18-C-0143Investigator Christina M. Annunziata, M.D., Ph.D.